Argos Therapeutics (ARGS) 7.41 $ARGS Argos Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 10:04 AM

Argos Therapeutics (ARGS) 7.41 $ARGS

Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 08, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the Jefferies 2016 Healthcare Conference to be held June 7-10 at the Grand Hyatt in New York City.
ARGS: 7.41 (-0.09)

Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 7.41 (-0.09)

Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
GlobeNewswire - Thu May 12, 3:05PM CDT
- Entered into Equity Financing for Up to $60 million -
ARGS: 7.41 (-0.09)

Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
GlobeNewswire - Thu May 05, 7:00AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 7.41 (-0.09)

3 Buy-Ranked Healthcare Stocks Building Momentum Now
Zacks Premium Research - Zacks Investment Research - Mon Apr 25, 3:57PM CDT
These healthcare stocks have posted double digit share price gains over the last month, but we're talking about another kind of momentum that makes these corporations worth betting on.
ARGS: 7.41 (-0.09), INVA: 11.35 (-0.21), VTAE: 10.19 (+0.07), GSK: 40.93 (-1.13)

Insider Bets Paying Off At ARGS As New 52-Week High Reached
MarketNewsVideo.com - Wed Apr 13, 12:13PM CDT
In trading on Wednesday, shares of Argos Therapeutics Inc. touched a new 52-week high of $9.41/share.
ARGS: 7.41 (-0.09)

Surging Earnings Estimates Signal Good News for Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:44AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 7.41 (-0.09)

Can The Uptrend Continue for Argos Therapeutics (ARGS)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:28AM CDT
Investors certainly have to be happy with Argos Therapeutics, Inc. (ARGS) and its short term performance
ARGS: 7.41 (-0.09)

Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 15 Annual Needham Healthcare Conference to be held April 12-13 at the Westin New York Grand Central in New York City.
ARGS: 7.41 (-0.09)

The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 4.00 (-0.19), ARGS: 7.41 (-0.09)

CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 5:12PM CDT
In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
ARGS: 7.41 (-0.09)

Argos Therapeutics reports 4Q loss
Automated Insights - Tue Mar 29, 3:59PM CDT
DURHAM, N.C. (AP) _ Argos Therapeutics Inc. (ARGS) on Tuesday reported a loss of $17.6 million in its fourth quarter.
ARGS: 7.41 (-0.09)

Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 3:30PM CDT
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 -
ARGS: 7.41 (-0.09)

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
GlobeNewswire - Wed Mar 23, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).
ARGS: 7.41 (-0.09)

Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
GlobeNewswire - Tue Mar 22, 3:05PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's fourth quarter and full-year 2015 financial results will be released after the market closes on Tuesday, March 29, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 7.41 (-0.09)

Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
GlobeNewswire - Tue Mar 22, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 6 Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference to be held on March 31, 2016 at the Apella Event Space Alexandria Center in New York City.
ARGS: 7.41 (-0.09)

Accenture (ACN) to Report Q2 Earnings: A Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:10AM CDT
Accenture plc (ACN) is set to report second-quarter fiscal 2016 results on Mar 24.
ARGS: 7.41 (-0.09), GME: 26.53 (-0.74), GIII: 42.54 (-0.60), ACN: 118.27 (-1.17)

Argos Therapeutics to Participate in Alliance for Regenerative Medicine Cell and Gene Therapy Investor Day
GlobeNewswire - Thu Mar 17, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced that it has entered into a securities purchase agreement for the sale of up to $60 million of Argos common stock and warrants in a private placement financing. Argos expects that this financing will fund operations into the second quarter of 2017, when the Company expects to have final data from its pivotal phase 3 ADAPT trial of AGS-003 (the "ADAPT Study"

.
ARGS: 7.41 (-0.09)

3 Reasons Momentum Stock Investors Will Love Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 7:45AM CST
Argos Therapeutics (ARGS) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
ARGS: 7.41 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...